Filing excerpt
Veklury sales decreased 69% to $86 million in the third quarter 2026 compared to the same period in 2025, primarily driven by lower rates of COVID-19-related hospitalizations.
Source: Autobound Signal API · 68 signals tracked for Gilead · updated
Get Gilead's live signals in Claude or ChatGPT, or by API
What changed at Gilead this week? Use Autobound signals for gilead.com.Veklury sales decreased 69% to $86 million due to lower COVID-19 hospitalizations, while Cell Therapy sales dropped 18% to $355 million amid competitive headwinds.
Filing excerpt
Veklury sales decreased 69% to $86 million in the third quarter 2026 compared to the same period in 2025, primarily driven by lower rates of COVID-19-related hospitalizations.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-8kbookingsDeclineGet every 8-K signal for Gilead and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Gilead this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/d4da128f-4e68-4544-8730-d559942e821e returns this record as JSON. POST /v1/companies/enrich returns every signal for gilead.com.
{
"signal_id": "d4da128f-4e68-4544-8730-d559942e821e",
"signal_type": "sec-8k",
"signal_subtype": "bookingsDecline",
"detected_at": "2026-11-03T07:04:54.919+00:00",
"company": {
"name": "Gilead",
"domain": "gilead.com"
},
"data": {
"detail": "Veklury sales decreased 69% to $86 million due to lower COVID-19 hospitalizations, while Cell Therapy sales dropped 18% to $355 million amid competitive headwinds. Solution providers addressing cell therapy manufacturing efficiency or clinical commercialization could target teams working to counter these declines.",
"metrics": {
"pct": -0.69,
"timeframe": "current_quarter",
"pct_context": "decrease in Veklury sales compared to same period in 2025",
"dollar_context": "Veklury sales in third quarter 2026",
"dollar_millions": 86
},
"summary": "Veklury sales drop 69% and Cell Therapy drops 18% in Q3 2026",
"excerpts": "Veklury sales decreased 69% to $86 million in the third quarter 2026 compared to the same period in 2025, primarily driven by lower rates of COVID-19-related hospitalizations.",
"relevance": 0.75,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/882095/000088209526000037/gild-20261029.htm",
"filing_date": "2026-10-29",
"filing_year": 2026,
"fiscal_year_end": "10/29",
"sales_relevance": "Sales effectiveness tools",
"signal_category": "revenue"
}
}
curl https://signals.autobound.ai/v1/signals/d4da128f-4e68-4544-8730-d559942e821e \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"gilead.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.